Long-term multiple metabolic abnormalities among healthy and high-risk people following nonsevere COVID-19
Authors:
- Chaiwat WashirasaksiriCWChaiwat Washirasaksiri
- Naruemit SayabovornNSNaruemit Sayabovorn
- Chayanis KositamongkolCKChayanis Kositamongkol
- Thanet ChaisathapholTCThanet Chaisathaphol
- Tullaya SitasuwanTSTullaya Sitasuwan
- Rungsima TinmaneeRTRungsima Tinmanee
- Chonticha AuesomwangCAChonticha Auesomwang
- Pongpol NimitpunyaPNPongpol Nimitpunya
- Methee ChayakulkeereeMCMethee Chayakulkeeree
- Pakpoom PhoompoungPPPakpoom Phoompoung
Open Access
- 31 August 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-15
Abstract
Few studies have identified the metabolic consequences of the post-acute phase of nonsevere COVID-19. This prospective study examined metabolic outcomes and associated factors in nonsevere, RT-PCR-confirmed COVID-19. The participants’ metabolic parameters, the prevalence of long-term multiple metabolic abnormalities (≥ 2 components), and factors influencing the prevalence were assessed at 1, 3, and 6 months post-onset. Six hundred individuals (mean age 45.5 ± 14.5 years, 61.7% female, 38% high-risk individuals) with nonsevere COVID-19 attended at least one follow-up visit. The prevalence of worsening metabolic abnormalities was 26.0% for BMI, 43.2% for glucose, 40.5% for LDL-c, 19.1% for liver, and 14.8% for C-reactive protein. Except for lipids, metabolic-component abnormalities were more prevalent in high-risk hosts than in healthy individuals. The prevalence of multiple metabolic abnormalities at the 6-month follow-up was 41.3% and significantly higher in high-risk than healthy hosts (49.2% vs 36.5%; P = 0.007). Factors independently associated with a lower risk of these abnormalities were being female, having dyslipidemia, and receiving at least 3 doses of the COVID-19 vaccine. These findings suggest that multiple metabolic abnormalities are the long-term consequences of COVID-19. For both high-risk and healthy individuals with nonsevere COVID-19, healthcare providers should monitor metabolic profiles, encourage healthy behaviors, and ensure complete vaccination.Keywords
Funding Information
- the Faculty of Medicine Siriraj Hospital, Mahidol University (R016534002)
This publication has 70 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- New-Onset Diabetes After Acute Kidney Injury Requiring DialysisDiabetes Care, 2018
- The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative DiseasesFrontiers in Immunology, 2018
- Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after InfectionScientific Reports, 2017
- Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- The global burden of liver disease: The major impact of ChinaHepatology, 2014
- Binding of SARS coronavirus to its receptor damages islets and causes acute diabetesActa Diabetologica, 2009
- Recovery pathway of post-SARS patientsThorax, 2005
- Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in HumansCirculation Research, 2005